​

ARS Pharmaceuticals Stock (NASDAQ:SPRY)

ForecastRevenueOwnershipFinancialsChartTranscripts
ARS Pharmaceuticals by TradingView

Previous Close

$5.62

52W Range

$4.91 - $13.15

50D Avg

$6.47

200D Avg

$8.56

Market Cap

$535.24M

Avg Vol (3M)

$2.02M

Beta

0.88

Div Yield

-

SPRY Company Profile

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

195

IPO Date

Dec 04, 2020

Website

SPRY Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
Product$72.19M$7.25M

Fiscal year ends in Dec 25 | Currency in USD

SPRY Financial Summary

Dec 25Dec 24Dec 23
Revenue$84.28M$89.15M$30.00K
Operating Income$-179.45M$-3.08M$-67.52M
Net Income$-171.30M$8.00M$-54.37M
EBITDA$-179.45M$-3.00M$-67.45M
Basic EPS$-1.74$0.08$-0.57
Diluted EPS$-1.74$0.08$-0.57

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 13, 26 | 4:30 PM
Q1 26May 15, 26 | 8:30 AM
Q4 25Mar 09, 26 | 8:30 AM

Peer Comparison

TickerCompany
TYRATyra Biosciences, Inc.
NBTXNanobiotix S.A.
GHRSGH Research PLC
KURAKura Oncology, Inc.
PVLAPalvella Therapeutics, Inc.
ABUSArbutus Biopharma Corp
RZLTRezolute, Inc.
SVRASavara Inc.
PROKProKidney Corp.
LENZLENZ Therapeutics, Inc.